Granted Patent
B2
US 9,587,022 · App. 14/133,256 · Granted Mar 7, 2017
Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
Assignee:
THE ROCKEFELLER UNIVERSITY
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.
Claims (2)
1. An anti-CD4 antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 2 and a light chain comprising the amino acid sequence of SEQ ID NO: 4.
2. A pharmaceutical composition comprising the antibody of claim 1 and at least one pharmaceutically acceptable carrier.
Assignments (2)
CONFIRMATORY LICENSE
Recorded Dec 18, 2015
From: ROCKEFELLER UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037334/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 6, 2014
From: SONG, RUIJIANG; HO, DAVID D.
To: THE ROCKEFELLER UNIVERSITY
Reel/Frame 032369/0168 →
Continuity (2)
Provisional Application
61738777
· Dec 18, 2012